US4765988A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Amosulalol hydrochloride long acting formulations
Assignee: Astellas Pharma Inc
•
Filing: 1987-05-05
•
Granted: 1988-08-23
•
Expires: 2007-05-05
Abstract
Abstract Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.
Inventors
- 👤 Takashi Sonobe
- 👤 Hiroshi Sugiura
- 👤 Tomoh Itoh
- 👤 Masayoshi Aruga
- 👤 Hiroitsu Kawata
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 07:26
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635; A61K31/00; A61K31/16; A61K31/18; A61K9/1617; A61K9/1652; A61K9/2095; A61P; A61P25/00; A61P25/02; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
67 words
A long acting pharmaceutical formulation comprising pharmaceutically effective amounts of amosulalol hydrochloride, from about 5 to about 50 weight percent of said formulation of an entero-soluble material selected from the group consisting of a methacrylic acid-ethyl acrylate copolymer, a methacrylic acid-methyl methacrylic copolymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and shellac, and the balance being at least one pharmaceutically acceptable additive excluding any pharmaceutically acceptable organic acid.
Claim 2
Dependent Claim
67 words
A long acting pharmaceutical formulation comprising pharmaceutically effective amounts of amosulalol hydrochloride, from about 5 to about 50 weight percent of said formulation of an entero-soluble material selected from the group consisting of a methacrylic acid-ethyl acrylate copolymer, a methacrylic acid-methyl methacrylic copolymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and shellac, and the balance being at least one pharmaceutically acceptable additive excluding any pharmaceutically acceptable organic acid.
Claim 3
Dependent Claim
15 words
A formulation of claim 1 wherein the entero-soluble material is a methacrylic acid-ethyl acrylate copolymer.
Claim 4
Dependent Claim
29 words
A method for the treatment of a subject afflicted with hypertension which comprises administering to said subject an antihypertensive effective amount of the long acting formulation of claim 1.
Claim 5
Dependent Claim
15 words
The method of claim 3 wherein the entero-soluble material is a methacrylic acid-ethyl acrylate copolymer.
Claim 6
Dependent Claim
14 words
The method of claim 3 wherein the entero-soluble material is a methacrylate acid-methylmethacrylate copolymer.
References Cited (Backward Citations)
US3520970A
Cited
US3538214A
Cited
US3835221A
Cited
US3775537A
Cited
US3954959A
Cited
US4083949A
Cited
US4361546A
Cited
US4289750A
Cited
US4367217A
Cited
US4427648A
Cited
US4438091A
Cited
US4724148A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-23 | 1992-02-22 | 1992-08-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-23 | 1996-02-22 | 1996-08-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-23 | 2000-02-22 | 2000-08-23 | $7700.00 | Window Closed / Lapsed |